Startups Are Using AI to Predict Responses to Cancer Drugs

null By Brian GormleyDec. 28, 2023 12:01 pm ET|WSJ ProPepper Bio Chief Executive Jon Hu, with Chief Scientific Officer Samantha Dale Strasser. Photo: Giro StudiosBiomedical startups are using artificial intelligence to predict the response patients will have to cancer treatments, aiming to increase the success of drugs in clinical trials and tailor therapies to individuals.As data accumulate from clinical trials and fields such as gene and protein research, AI is helping scientists sift through large volumes of information to uncover signatures that correlate with response—or resistance—to treatment. Startups are using it to predict which drugs are likely to work in clinical studies and create tests to help doctors choose treatments.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

A person who loves writing, loves novels, and loves life.Seeking objective truth, hoping for world peace, and wishing for a world without wars.

Opinion Dec 29, 2023 Add to Reading List

Startups Are Using AI to Predict Responses to Cancer Drugs

null

By Brian Gormley

Dec. 28, 2023 12:01 pm ET|WSJ Pro

Pepper Bio Chief Executive Jon Hu, with Chief Scientific Officer Samantha Dale Strasser. Photo: Giro Studios

Biomedical startups are using artificial intelligence to predict the response patients will have to cancer treatments, aiming to increase the success of drugs in clinical trials and tailor therapies to individuals.

As data accumulate from clinical trials and fields such as gene and protein research, AI is helping scientists sift through large volumes of information to uncover signatures that correlate with response—or resistance—to treatment. Startups are using it to predict which drugs are likely to work in clinical studies and create tests to help doctors choose treatments.